Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 8, 2013, Pages 1183-1193

  Batista, Ana Rita ^a,b   Sena Esteves, Miguel ^c   Saraiva, Maria João ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cellular models; Intracellular aggregation; Leptomeningeal amyloidosis; Lysosomes; N glycosylation; Transthyretin

Indexed keywords

PREALBUMIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CELL AGGREGATION; CELLULAR DISTRIBUTION; CHOROID PLEXUS; CONTROLLED STUDY; DEGRADATION; DISEASE ASSOCIATION; GLYCOSYLATION; HUMAN; HUMAN CELL; LEPTOMENINGEAL AMYLOIDOSIS; LIVER CELL; LYSOSOME; MASS SPECTROMETRY; MOUSE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; ANIMALS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CHOROID PLEXUS; GLYCOSYLATION; HEK293 CELLS; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; LYSOSOMES; MICE; MICE, TRANSGENIC; PREALBUMIN;

EID: 84877340049     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.04.001     Document Type: Article

References (49)

1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952, 75:408-427.
2. Vidal R., Garzuly F., Budka H., Lalowski M., Linke R.P., Brittig F., Frangione B., Wisniewski T. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am. J. Pathol. 1996, 148:361-366.
3. Brett M., Persey M.R., Reilly M.M., Revesz T., Booth D.R., Booth S.E., Hawkins P.N., Pepys M.B., Morgan-Hughes J.A. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain 1999, 122(Pt 2):183-190.
4. Benson M.D. Leptomeningeal amyloid and variant transthyretins. Am. J. Pathol. 1996, 148:351-354.
5. Sekijima Y., Hammarström P., Matsumura M., Shimizu Y., Iwata M., Tokuda T., Ikeda S.-I., Kelly J.W. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab. Invest. 2003, 83:409-417.
6. Plante-Bordeneuve V., Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011, 10:1086-1097.
7. Quintas A., Vaz D.C., Cardoso I., Saraiva M.J., Brito R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 2001, 276:27207-27213.
8. Sekijima Y., Wiseman R.L., Matteson J., Hammarström P., Miller S.R., Sawkar A.R., Balch W.E., Kelly J.W. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005, 121:73-85.
9. Sena-Esteves M., Tebbets J.C., Steffens S., Crombleholme T., Flake A.W. Optimized large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods 2004, 122:131-139.
10. Cardoso I., Almeida M.R., Ferreira N., Arsequell G., Valencia G., Saraiva M.J. Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochem. J. 2007, 408:131-138.
11. Hoffmann C., Gaietta G., Zürn A., Adams S.R., Terrillon S., Ellisman M.H., Tsien R.Y., Lohse M.J. Fluorescent labeling of tetracysteine-tagged proteins in intact cells. Nat. Protoc. 2010, 5:1666-1677.
12. Episkopou V., Maeda S., Nishiguchi S., Shimada K., Gaitanaris G.A., Gottesman M.E., Robertson E.J. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:2375-2379.
13. Broekman M.L., Baek R.C., Comer L.A., Fernandez J.L., Seyfried T.N., Sena-Esteves M. Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol. Ther. 2007, 15:30-37.
14. Nathwani A.C., Gray J.T., Ng C.Y., Zhou J., Spence Y., Waddington S.N., Tuddenham E.G., Kemball-Cook G., McIntosh J., Boon-Spijker M., Mertens K., Davidoff A.M. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 2006, 107:2653-2661.
15. McCarty D.M., Fu H., Monahan P.E., Toulson C.E., Naik P., Samulski R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003, 10:2112-2118.
16. Broekman M.L., Comer L.A., Hyman B.T., Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006, 138:501-510.
17. Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Tinevez J.Y., White D.J., Hartenstein V., Eliceiri K., Tomancak P., Cardona A. Fiji: an open-source platform for biological-image analysis. Nat. Methods 2012, 9:676-682.
18. Sato T., Susuki S., Suico M.A., Miyata M., Ando Y., Mizuguchi M., Takeuchi M., Dobashi M., Shuto T., Kai H. Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J. 2007, 26:2501-2512.
19. Dickson P.W., Howlett G.J., Schreiber G. Rat transthyretin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain. J. Biol. Chem. 1985, 260:8214-8219.
20. Terasaki T., Hosoya K. Conditionally immortalized cell lines as a new in vitro model for the study of barrier functions. Biol. Pharm. Bull. 2001, 24:111-118.
21. Thomas P., Smart T.G. HEK293 cell line: a vehicle for the expression of recombinant proteins. J. Pharmacol. Toxicol. Methods 2005, 51:187-200.
22. Griffin B.A., Adams S.R., Tsien R.Y. Specific covalent labeling of recombinant protein molecules inside live cells. Science 1998, 281:269-272.
23. Griffin B.A., Adams S.R., Jones J., Tsien R.Y. Fluorescent labeling of recombinant proteins in living cells with FlAsH. Methods Enzymol. 2000, 327:565-578.
24. Hammarström P., Sekijima Y., White J.T., Wiseman R.L., Lim A., Costello C.E., Altland K., Garzuly F., Budka H., Kelly J.W. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?. Biochemistry 2003, 42:6656-6663.
25. Sato T., Sako Y., Sho M., Momohara M., Suico M.A., Shuto T., Nishitoh H., Okiyoneda T., Kokame K., Kaneko M., Taura M., Miyata M., Chosa K., Koga T., Morino-Koga S., Wada I., Kai H. STT3B-dependent posttranslational N-glycosylation as a surveillance system for secretory protein. Mol. Cell 2012, 47:99-110.
26. Parekh R.B., Tse A.G., Dwek R.A., Williams A.F., Rademacher T.W. Tissue-specific N-glycosylation, site-specific oligosaccharide patterns and lentil lectin recognition of rat Thy-1. EMBO J. 1987, 6:1233-1244.
27. Parekh R.B., Dwek R.A., Thomas J.R., Opdenakker G., Rademacher T.W., Wittwer A.J., Howard S.C., Nelson R., Siegel N.R., Jennings M., Harakas N., Feder J. Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochemistry 1989, 28:7644-7662.
28. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32.
29. Blott E.J., Griffiths G.M. Secretory lysosomes. Nat. Rev. Mol. Cell Biol. 2002, 3:122-131.
30. Wang S., Thibault G., Ng D.T. Routing misfolded proteins through the multivesicular body (MVB) pathway protects against proteotoxicity. J. Biol. Chem. 2011, 286:29376-29387.
31. Cardelli J.A., Richardson J., Miears D. Role of acidic intracellular compartments in the biosynthesis of dictyostelium lysosomal enzymes. The weak bases ammonium chloride and chloroquine differentially affect proteolytic processing and sorting. J. Biol. Chem. 1989, 264:3454-3463.
32. Anelli T., Sitia R. Protein quality control in the early secretory pathway. EMBO J. 2008, 27:315-327.
33. Kubota H. Quality control against misfolded proteins in the cytosol: a network for cell survival. J. Biochem. 2009, 146:609-616.
34. Susuki S., Sato T., Miyata M., Momohara M., Suico M.A., Shuto T., Ando Y., Kai H. The endoplasmic reticulum-associated degradation of transthyretin variants is negatively regulated by BiP in mammalian cells. J. Biol. Chem. 2009, 284:8312-8321.
35. Colosimo A., Goncz K.K., Holmes A.R., Kunzelmann K., Novelli G., Malone R.W., Bennett M.J., Gruenert D.C. Transfer and expression of foreign genes in mammalian cells. Biotechniques 2000, 29:314-318. (320-312, 324 passim).
36. Biroccio A., Del Boccio P., Panella M., Bernardini S., Di Ilio C., Gambi D., Stanzione P., Sacchetta P., Bernardi G., Martorana A., Federici G., Stefani A., Urbani A. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 2006, 6:2305-2313.
37. Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R. Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 2004, 4:454-465.
38. Ruggeberg S., Horn P., Li X., Vajkoczy P., Franz T. Detection of a gamma-carboxy-glutamate as novel post-translational modification of human transthyretin. Protein Pept. Lett. 2008, 15:43-46.
39. Terazaki H., Ando Y., Suhr O., Ohlsson P.I., Obayashi K., Yamashita T., Yoshimatsu S., Suga M., Uchino M., Ando M. Post-translational modification of transthyretin in plasma. Biochem. Biophys. Res. Commun. 1998, 249:26-30.
40. Teixeira A.C., Saraiva M.J. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. J. Cell. Mol. Med. 2013, 17:429-443.
41. Sato T., Sako Y., Sho M., Momohara M., Suico M.A., Shuto T., Nishitoh H., Okiyoneda T., Kokame K., Kaneko M., Taura M., Miyata M., Chosa K., Koga T., Morino-Koga S., Wada I., Kai H. STT3B-dependent posttranslational N-glycosylation as a surveillance system for secretory protein. Mol. Cell 2012, 47:99-110.
42. Shental-Bechor D., Levy Y. Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8256-8261.
43. Ruiz-Canada C., Kelleher D.J., Gilmore R. Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. Cell 2009, 136:272-283.
44. Nascimento-Ferreira I., Santos-Ferreira T., Sousa-Ferreira L., Auregan G., Onofre I., Alves S., Dufour N., Colomer Gould V.F., Koeppen A., Deglon N., Pereira de Almeida L. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Brain 2011, 134:1400-1415.
45. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
46. Kirik D., Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci. 2003, 26:386-392.
47. Saraiva M.J., Costa P.P., Goodman D.S. Biochemical marker in familial amyloidotic polyneuropathy, Portuguese type. Family studies on the transthyretin (prealbumin)-methionine-30 variant. J. Clin. Invest. 1985, 76:2171-2177.
48. Mitsuhashi S., Yazaki M., Tokuda T., Sekijima Y., Washimi Y., Shimizu Y., Ando Y., Benson M.D., Ikeda S.-I. Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis. Amyloid 2005, 12:216-225.
49. Altland K., Benson M.D., Costello C.E., Ferlini A., Hazenberg B.P.C., Hund E., Kristen A.V., Linke R.P., Merlini G., Salvi F., Saraiva M.J., Singer R., Skinner M., Winter P. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis 2007, 28:2053-2064.